Spots Global Cancer Trial Database for Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Official Title: Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Study ID: NCT00298064
Interventions
Study Description
Brief Summary: The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.
Detailed Description: This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future. This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of New Mexico, Albuquerque, New Mexico, United States
Contact Details
Name: Claire Verschraegen, MD
Affiliation: University of New Mexico
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
